TICKERNERD
Menu
RNXTRNXTHealthcare · Biotechnology

RNXT Stock Forecast: RenovoRx, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$1.76
−0.56% on the day

The 4 Wall Street analysts covering RenovoRx, Inc. hold a median 12-month price target of $5.5 — +212.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 11 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$79.9M
Ticker Nerd rank
38 / 100
Median analyst target
$5.50
Analysts covering
4
Revenue$909K+115.4% y/y
Operating income−$3.3M
Net income−$2.9M
Free cash flow−$2.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−25.7%
1M
+53.0%
YTD
+109.5%
1Y
+41.9%
From 52W high
−30.2%
From 52W low
+140.1%
$0.73
$2.52
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RNXT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores RenovoRx, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Sept 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
78
Revisions
76
Accruals
50
Growth
49
Momentum
47
Quality
29
Volatility
27
Value
27
Issuance
18

Size (78): Smaller than most of the companies we track.

Issuance (18): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RNXT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RNXT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26RNXTHigh $14.50Median $5.50Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $3.00Median $5.50High $14.50

The green dot is the last close — the median target sits +212.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
28 Aug 2026Ascendiant CapitalMaintainsBuy$14 → $15
1 June 2026Ascendiant CapitalMaintainsBuy$14 → $14
1 June 2026Ascendiant CapitalMaintainsBuy—
9 Apr 2026Ascendiant CapitalMaintainsBuy—
8 Apr 2026HC Wainwright & Co.ReiteratesBuy—
17 Feb 2026Ascendiant CapitalMaintainsBuy—
21 Nov 2025Ascendiant CapitalMaintainsBuy—
25 Aug 2025Ascendiant CapitalMaintainsBuy—
5 June 2025Ascendiant CapitalMaintainsBuy—
19 May 2025HC Wainwright & Co.ReiteratesBuy—
28 Apr 2025Ascendiant CapitalMaintainsBuy—
4 Apr 2025HC Wainwright & Co.ReiteratesBuy—
27 Mar 2025HC Wainwright & Co.InitiatesBuy—
10 Dec 2024Ascendiant CapitalMaintainsBuy—
12 Sept 2024Ascendiant CapitalMaintainsBuy—
17 June 2024Ascendiant CapitalInitiatesBuy—
2 Feb 2024Alliance Global PartnersInitiatesBuy—
15 Nov 2023Maxim GroupDowngradeHold—
18 Aug 2023Roth MKMMaintainsBuy—
1 Nov 2021Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RNXT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RNXT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, RenovoRx, Inc. returned +41.9% against +17.5% for the S&P 500, dividends included.

RNXT vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Oct 25Jan 26Apr 26Jul 26RNXTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RNXT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

RenovoRx, Inc. (RNXT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−5.5×

Cheaper than 90% of US stocks

Price / sales
40.4×

Cheaper than 6% of US stocks

Price / book
8.9×

Cheaper than 11% of US stocks

EV / EBITDA
−5.4×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
115.4%

Higher than 93% of US stocks

Earnings growth (YoY)
115.4%

Higher than 85% of US stocks

Gross margin
84.3%

Higher than 93% of US stocks

Operating margin
−368.4%

Higher than 8% of US stocks

Net margin
70.9%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−125.2%

Higher than 11% of US stocks

Return on assets
−64.9%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

RenovoRx, Inc. (RNXT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • RenovoRx, Inc. has a market value of $79.9M and an enterprise value of $70.8M.

  • Revenue in the twelve months to 30 June 2026: $2.0M. The latest quarter grew 115.4% year on year.

  • Net income over the same four quarters: −$12.3M, a −621.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$11.9M.

  • Shares outstanding: 45.1M.

  • Trailing P/E: −5.5×; forward P/E: −14.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • RenovoRx, Inc. employs 17 people — $116K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 11 Sept 2026

Data provided by Twelve Data

Peers

RNXT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RNXTRenovoRx, Inc.$79.9M
38
MAIAMAIA Biotechnology, Inc.$78.9M
22
TELOTelomir Pharmaceuticals, Inc.$80.5M
13
ALDXAldeyra Therapeutics, Inc.$80.8M
50
BSEMBioStem Technologies, Inc.$76.9M
54
FBIOFortress Biotech, Inc.$83.7M
78
PTHSPelthos Therapeutics, Inc.$83.8M
20

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own RenovoRx, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RNXT news & analysis

RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th

GlobeNewsWire · 2 Sept 2026neutral

RenovoRx announced that CEO Shaun Bagai and CFO Mark Voll will present at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14th-16th. The company develops targeted oncology therapies and commercializes the RenovoCath drug-delivery device.

Why it matters — A presentation at a major investment conference gives RNXT senior leadership a platform to share the company's story and updates with investors and the broader financial community.

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

GlobeNewsWire · 25 Aug 2026positive

RenovoRx announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial in the journal Cancer Chemotherapy and Pharmacology. The data showed approximately 51% tumor-site drug extraction, decreased systemic exposure, and a significant correlation between drug metabolite levels and tumor marker reduction, supporting the company's TAMP platform for targeted drug delivery in locally advanced pancreatic cancer.

Why it matters — A RNXT watcher would care because peer-reviewed PK/PD evidence from the Phase III TIGeR-PaC trial strengthens the scientific validation of the company's TAMP targeted drug-delivery platform, a key pillar of its oncology therapy pipeline.

RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewsWire · 21 Aug 2026positive

RenovoRx announced it received written notification from Nasdaq confirming the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Why it matters — This removes the risk of delisting from Nasdaq related to the minimum bid price requirement, supporting RenovoRx's continued listing status.

RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment

GlobeNewsWire · 20 Aug 2026positive

RenovoRx announced it received a Notice of Allowance for a new U.S. patent covering RenovoCath, an advanced dual-occlusion catheter for targeted therapeutic drug-delivery in cancer treatment. The company continues to strengthen its intellectual property portfolio, which now includes 20 issued or allowed patents and 13 pending patents supporting RenovoCath commercialization.

Why it matters — A watcher would care because the patent allowance strengthens RenovoRx's intellectual property position for RenovoCath as its commercial and clinical programs advance.

RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers

MarketBeat · 17 Aug 2026positive

RenovoRx executives and physician speakers discussed locally advanced pancreatic cancer treatment, the company's Trans-Arterial Micro-Perfusion (TAMP) platform, and commercialization progress for its RenovoCath delivery device during a JonesTrading-hosted webinar. The company is targeting a 2027 readout for its TIGeR-PaC trial while RenovoCath expands to 21 centers.

Why it matters — RNXT watchers would care because the webinar highlights ongoing commercialization progress for RenovoCath and the anticipated 2027 TIGeR-PaC data readout, key milestones for the company.

FAQ

Frequently asked questions about RNXT stock

What is the RNXT stock price forecast for 2026-2027?

The 4 Wall Street analysts covering RenovoRx, Inc. have a median 12-month price target of $5.5, with estimates ranging from $3 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RNXT stock a buy right now?

Of the 4 analysts covering RenovoRx, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks RenovoRx, Inc. 38 out of 100 across roughly 4,600 US stocks as at 11 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RNXT?

As at 11 Sept 2026, RenovoRx, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (78 of 100).

Will RNXT stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +212.5% from the last close, and Ticker Nerd's factor model ranks RenovoRx, Inc. 38 out of 100 as at 11 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RNXT stock forecast for 2030?

No analyst covering RenovoRx, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RNXT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $15 over the next 12 months.

How has RNXT stock performed over the past year?

RenovoRx, Inc. returned +41.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does RenovoRx, Inc. do?

RenovoRx, Inc. is a life sciences company focused on targeted oncology therapies and localized drug delivery for cancer treatment.

What is the latest news on RNXT?

The most recent item we track (GlobeNewsWire, 2 Sept 2026): "RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th". RenovoRx announced that CEO Shaun Bagai and CFO Mark Voll will present at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14th-16th. The company develops targeted oncology therapies and commercializes the RenovoCath drug-delivery device.

Company

About RenovoRx, Inc.

RenovoRx, Inc. is a life sciences company focused on targeted oncology therapies and localized drug delivery for cancer treatment. Its core offering includes RenovoCath, an FDA-cleared local drug delivery device designed to deliver chemotherapy directly to tumor sites while limiting exposure to healthy tissue. The company also develops its Trans-Arterial Micro-Perfusion therapy platform, which is intended for precise intra-arterial delivery of cancer treatments in solid tumors. RenovoRx’s work centers on addressing high unmet medical needs in oncology, with particular emphasis on improving how therapies are administered in clinical settings. The company operates at the intersection of medical technology and biopharmaceutical development, serving the broader cancer care market through device-enabled drug delivery solutions.

CEO Mr. Shaun R. Bagai · 17 employees · United States · https://renovorx.com